Short Summary
Visa's claims against Cortex MCP were upheld by the PTAB Director in a review of the Final Written Decision. The Board confirmed that Oborne discloses the token verification limitation central to Visa's patent.
Detailed Summary
In this Delegated Director Review, the Patent Trial and Appeal Board affirmed its Final Written Decision, denying Cortex MCP’s request for reversal. The Panel found no error in the Board's determination that the challenged claims of U.S. Patent No. 9,251,531 B2 were unpatentable over Oborne. Specifically, the Director confirmed that the Board properly evaluated claim construction and did not introduce a new theory of unpatentability, agreeing that Oborne discloses verification through its disclosure of pre-funding or pre-authorizing tokens.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Visa, Inc. vs Cortex MCP, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Google LLCvsSecure Communication Technologies, LLC
Google’s IPR against a proximity‑based coupon patent resulted in 20 of 22 challenged claims being found unpatentable, with only two claims surviving.
Google LLCvsProxense, LLC
Google and Proxense settled their dispute, leading the PTAB to terminate the IPR over Proxense’s Bluetooth proximity patent.
Google LLC et al.vsSoftView LLC
Google has filed an IPR petition seeking to invalidate claims 1‑37 of SoftView’s ’628 patent, asserting obviousness over Zaurus, Pad++, and SVG references and arguing the claims are indistinct from already invalidated claims in related patents.
Microsoft CorporationvsToutVirtual, Inc.
Microsoft files an IPR petition challenging ToutVirtual’s 2023 ‘Virtual Systems Management’ patent, asserting that all 14 claims are obvious over a suite of prior‑art virtualization references.
AZURITY PHARMACEUTICALS, INC.vsHelsinn Healthcare S.A.
Azurity has filed an IPR petition seeking cancellation of 23 claims of Helsinn’s anti‑emetic patent covering netupitant, palonosetron and dexamethasone regimens. The challenger alleges obviousness over multiple prior‑art references and disputes the asserted unexpected synergy. No decision has been issued yet.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.